Table 1.
Baseline demographics and disease characteristics of psoriasis patients.
| Parameter | FLD (n=308) | non-FLD (n=366) | P value |
|---|---|---|---|
| Demographics | |||
| Gender, male, n (%) | 251 (81.5%) | 279 (76.2%) | 0.097 |
| Age, median (IQR) | 55 (40, 65) | 60 (45, 67) | 0.008 |
| Family history of psoriasis, n (%) | 58 (18.8%) | 60 (16.4%) | 0.407 |
| BMI (kg/m²), median (IQR) | 26.1 (23.9, 29.0) | 23.6 (21.2, 25.7) | < 0.001 |
| Smoking, n (%) | 140 (45.5%) | 139 (38%) | 0.050 |
| Drinking, n (%) | 67 (21.8%) | 84 (23%) | 0.710 |
| Comorbidity | |||
| Hypertension, n (%) | 123 (39.9%) | 109 (29.8%) | 0.006 |
| Type 2 diabetes mellitus, n (%) | 56 (18.2%) | 56 (15.3%) | 0.317 |
| PSA, n (%) | 68 (22.1%) | 75 (20.5%) | 0.616 |
| Evaluation of psoriasis | |||
| Duration (years), median (IQR) | 10 (6, 20) | 10 (6, 20) | 0.973 |
| Prior-MTX, n (%) | 135 (43.8%) | 160 (43.7%) | 0.976 |
| Prior-acitretin, n (%) | 160 (51.9%) | 198 (54.1%) | 0.577 |
| BSA (%), median (IQR) | 30 (15, 41) | 25 (14, 40) | 0.167 |
| PASI, median (IQR) | 15.3 (11.6, 21.0) | 15.0 (11.5, 21.0) | 0.318 |
| Hematological results | |||
| Leukocyte (*109/L), median (IQR) | 6.6 (5.6, 7.8) | 6.2 (5.3, 7.7) | 0.004 |
| Thrombocyte (*109/L), median (IQR) | 211.5 (174.8, 263.3) | 208 (170.3, 256.5) | 0.343 |
| Lymphocyte (*109/L), median (IQR) | 1.9 (1.5, 2.3) | 1.8 (1.4, 2.1) | < 0.001 |
| Neutrophil (*109/L), median (IQR) | 3.9 (3.3, 5.0) | 3.9 (3.0, 4.9) | 0.066 |
| NLR, median (IQR) | 2.1 (1.6, 2.9) | 2.2 (1.6, 3.1) | 0.320 |
| dNLR, median (IQR) | 1.5 (1.2, 2.0) | 1.6 (1.2, 2.1) | 0.571 |
| SII, median (IQR) | 449.0 (317.1, 668.7) | 461.8 (305.4, 663.5) | 0.738 |
| Fasting blood glucose (mmol/L), median (IQR) | 5.4 (4.9, 6.4) | 5.1 (4.7, 5.7) | < 0.001 |
| Triglyceride (mmol/L), median (IQR) | 1.7 (1.2, 2.3) | 1.3 (1.0, 1.7) | < 0.001 |
| TyG, median (IQR) | 9.4 (9.0, 9.8) | 9.1 (8.7, 9.5) | < 0.001 |
| TyG-BMI, median (IQR) | 249.8 (222.6, 276.0) | 215.9 (191.6, 235.8) | < 0.001 |
FLD, fatty liver disease; IQR, interquartile range; BMI, body mass index; PSA, psoriatic arthritis; MTX, methotrexate; BSA, body surface area; PSAI, psoriasis area and severity index; NLR, neutrophil-to-lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; SII, Systemic Immune Inflammation Index; TyG, triglyceride-glucose; TyG-BMI, triglyceride glucose-body mass index.
* represents the unit of counting.